A team of scientists at the University of British Columbia’s TRIUMF facility are celebrating a major triumph after signing a deal to produce a rare cancer drug which previously relied on nuclear waste.
The rare drug, a radioisotope known as actinium-225, started making headlines about five years ago when four treatments of it were administered to a German man who was just weeks from death and suffering from multiple cancerous tumours. Eight months later, the tumours had disappeared.
The B.C. lab has figured out how to produce actinium-225 at their facility without using nuclear waste, which could mean the ability to produce thousands of doses of the drug. Jordan Armstrong explains how it could make a major difference.
For more info, please go to https://globalnews.ca/news/7541900/ubc-facility-rare-drug/
Subscribe to Global News Channel HERE: http://bit.ly/20fcXDc
Like Global News on Facebook HERE: http://bit.ly/255GMJQ
Follow Global News on Twitter HERE: http://bit.ly/1Toz8mt
Follow Global News on Instagram HERE: https://bit.ly/2QZaZIB